{"name":"Trygg Pharma, Inc.","slug":"trygg-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AKR-963","genericName":"AKR-963","slug":"akr-963","indication":"Inflammatory and immune-mediated disorders (specific indication under investigation in Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"AKR-963","genericName":"AKR-963","slug":"akr-963","phase":"phase_3","mechanism":"AKR-963 is a selective agonist of the adenosine A1 receptor that modulates immune and inflammatory responses.","indications":["Inflammatory and immune-mediated disorders (specific indication under investigation in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9DcDlCZHFUNTgzY2ZsUXJ5d3VCdVpqc0hOb0t6bm1PUUo2RXlyQmRiM01kLU01MHp2alc2TkxIVUNlRGttOGVhNVcwRFM0YzAtc1ViSW5kT1RmZ0s0emtvN0FKOUR4MFc5VExKSTFkYWFOcEJqUV9odW9n?oc=5","date":"2024-09-10","type":"deal","source":"SupplySide Supplement Journal","summary":"FMC Acquires Omega-3 Producer Epax - SupplySide Supplement Journal","headline":"FMC Acquires Omega-3 Producer Epax","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNRzhhTUx1aEFSTWxkZTkxWE5zeE5US3F3cXJBY1p5UXNaS1VpZmh6S0VUR1liYnJaclloOERDanFBXzkyTEFfQmtlLXgtOTBwczZKeHdRZmVXWktVcXJ3dnJNdWtkN2ZkTmxaVU10dzM2ME81M0R5Z2pUTnQtZ1d3TVdxaVVndkVxVmNaU2Q3blEyM05UaTBKdlBTQmhySWFPdmYzU09yRHlJUQ?oc=5","date":"2014-06-04","type":"regulatory","source":"Nutritional Outlook","summary":"FDA Approves Three More Omega-3 Drugs. Is This Good or Bad News for Supplements? - Nutritional Outlook","headline":"FDA Approves Three More Omega-3 Drugs. Is This Good or Bad News for Supplements?","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBaUExPM2FMYktlM3hiT19yaEZqb1I5VkFBbVA5bEdBSFRWQk9hdjREZGt3dGo4QXV0Z3l3d2MzSzhNbnBPVlcxcEhXYkNkUDBEZ1lJaTVmN1lOOTlxTUpJYktFU0Z0emVPamVMV3N1Qk00X3U1?oc=5","date":"2001-05-09","type":"pipeline","source":"Pharmaceutical Technology","summary":"Trygg Pharma’s Seal Sands Bulk Pharmaceuticals Facility, Teesside, UK - Pharmaceutical Technology","headline":"Trygg Pharma’s Seal Sands Bulk Pharmaceuticals Facility, Teesside, UK","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}